BaldnessNCT07048626
Impact of Low-Level Laser Therapy on Hair Regrowth Post PRP Treatment
A study testing PRP treatment and low level laser therapy post prp treatment in people with Baldness, run by Superior University at 1 site in Pakistan.
Trial summary
Low-level laser stimulates cells in the hair follicles, which promotes hair growth. The patient's own blood platelets are used in platelet-rich plasma treatment to encourage hair growth. Combining low-level laser treatment with platelet-rich plasma will promote hair growth in patients. Read more about this study
- Who is it for?
- Ages 20 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Baldness
- What is being tested?
- PRP treatment and low level laser therapy post prp treatment
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- 1 sitePakistan
- Study dates
- 17 Mar 2025to 28 Feb 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adults between 18-35 years diagnosed with androgenic alopecia or other non-scarring hair loss conditions.
- Having the Norwood-Hamilton scale placed in stages I-V for men Ludwig scale in stages I-III for women .
Who cannot join
- Use of systemic medications (e.g., corticosteroids, immunosuppressants) or treatments affecting hair regrowth within the last 3 months.
- History of hypersensitivity or adverse reactions to laser therapy
- Active systemic diseases such as uncontrolled diabetes, autoimmune disorders, or malignancies
- Pregnant or breastfeeding individuals.
- Patients with pacemakers or implanted medical devices contraindicated with low level laser therapy.
- History of hair transplant surgery in the treatment area
Trial locations and contacts
1 site in 1 country.
About this study
Low-level laser stimulates cells in the hair follicles, which promotes hair growth. The patient's own blood platelets are used in platelet-rich plasma treatment to encourage hair growth. Combining low-level laser treatment with platelet-rich plasma will promote hair growth in patients.
Read the detailed description
To determine the impact of low-level laser therapy on hair regrowth following prp treatment.
This will be case control study conducted on 22 participants with androgenetic alopecia (AGA).
- Conditions
- Baldness
- Being tested
- PRP treatment, low level laser therapy post prp treatment
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PRP treatmentCombination product
PRP treatment involves drawing a blood sample, processing it to concentrate platelets, and then injecting that concentrated plasma back into the body, typically at the site of an injury or area needing regeneration. The procedure aims to utilize the growth factors within the platelets to accelerate healing and tissue repair.
low level laser therapy post prp treatmentCombination product
will receive low-level laser therapy post prp treatment upto 12 weeks .Low-level laser therapy (LLLT) is a non-invasive treatment for hair loss that uses low-intensity laser light to stimulate hair follicles and improve blood circulation. It's often used on its own or combined with other therapies like PRP.
| Study group | Role | What they receive |
|---|---|---|
| PRP treatment | Experimental | Not described Receives: Combination Product: PRP treatment |
| low leve laser therapy post prp treatment | Active comparator | Not described Receives: Combination Product: low level laser therapy post prp treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Physician's Global Assessment (PGA) scale
The Physician's Global Assessment (PGA) scale is a tool used by physicians to evaluate the overall severity of a patient's disease. It's a subjective assessment, typically on a scale of 0 to 3 or 0 to 4, with higher scores indicating more severe disease activity. The PGA focuses on the overall disease activity, considering both the severity of active manifestations and relevant laboratory results, excluding organ damage and subjective findings unrelated to disease activity
Measured: 12 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2025
- Study start17 Mar 2025
- Primary completion1 Sep 2025 (estimated)
- Study completion28 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BaldnessStudies of the same condition, open and under way.
- More trials run by Superior UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- Superior University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Muhammad Naveed Babur, Superior University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07048626
- Sponsor's protocol ID
- MSAHSW/Batch-Fall23/903
- Status last verified
- Jun 2025
- First submitted
- 24 Jun 2025
- Last updated
- 2 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Low-Level Laser Therapy on Hair Regrowth Post PRP Treatment
- ClinicalTrials.gov ID
- NCT07048626
- Acronym / sponsor ID
- MSAHSW/Batch-Fall23/903
- Conditions
- Baldness
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 22 participants (actual)
- Lead sponsor
- Superior UniversityUniversity, hospital or other
- Study start
- 17 Mar 2025 (actual)
- Primary completion
- 1 Sep 2025 (estimated)
- Study completion
- 28 Feb 2026 (estimated)
- First posted
- 2 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Low-level laser stimulates cells in the hair follicles, which promotes hair growth. The patient's own blood platelets are used in platelet-rich plasma treatment to encourage hair growth. Combining low-level laser treatment with platelet-rich plasma will promote hair growth in patients.
Detailed description
To determine the impact of low-level laser therapy on hair regrowth following prp treatment.
This will be case control study conducted on 22 participants with androgenetic alopecia (AGA).
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PRP treatment | Experimental | Combination Product: PRP treatment |
| low leve laser therapy post prp treatment | Active comparator | Combination Product: low level laser therapy post prp treatment |
Who may qualify
- Ages
- 20 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Adults between 18-35 years diagnosed with androgenic alopecia or other non-scarring hair loss conditions.
- Having the Norwood-Hamilton scale placed in stages I-V for men Ludwig scale in stages I-III for women .
Key exclusion criteria (6 listed)
- Use of systemic medications (e.g., corticosteroids, immunosuppressants) or treatments affecting hair regrowth within the last 3 months.
- History of hypersensitivity or adverse reactions to laser therapy
- Active systemic diseases such as uncontrolled diabetes, autoimmune disorders, or malignancies
- Pregnant or breastfeeding individuals.
- Patients with pacemakers or implanted medical devices contraindicated with low level laser therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PRP treatmentPRP treatment involves drawing a blood sample, processing it to concentrate platelets, and then injecting that concentrated plasma back into the body, typically at the site of an injury or area needing regeneration. The procedure aims to utilize the growth factors within the platelets to accelerate healing and tissue repair. | Combination product | PRP treatment |
| low level laser therapy post prp treatmentwill receive low-level laser therapy post prp treatment upto 12 weeks .Low-level laser therapy (LLLT) is a non-invasive treatment for hair loss that uses low-intensity laser light to stimulate hair follicles and improve blood circulation. It's often used on its own or combined with other therapies like PRP. | Combination product | low leve laser therapy post prp treatment |
Primary outcome
Physician's Global Assessment (PGA) scale
Time frame: 12 Months
The Physician's Global Assessment (PGA) scale is a tool used by physicians to evaluate the overall severity of a patient's disease. It's a subjective assessment, typically on a scale of 0 to 3 or 0 to 4, with higher scores indicating more severe disease activity. The PGA focuses on the overall disease activity, considering both the severity of active manifestations and relevant laboratory results, excluding organ damage and subjective findings unrelated to disease activity
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Baldness
Active, not recruitingPhase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Severe Alopecia Areata
RecruitingPhase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Active, not recruitingObservational study
Litfulo Capsules Special Investigation
Alopecia Areata
Active, not recruitingObservational study
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
Alopecia Areata
Active, not recruitingObservational study
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia Areata
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PRP treatment and low level laser therapy post prp treatment in people with Baldness, run by Superior University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Physician's Global Assessment (PGA) scale (time frame: 12 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2025.